Skip to main content
. 2019 May 2;36(6):1291–1303. doi: 10.1007/s12325-019-00957-y

Table 1.

Demographic and clinical characteristics of patients at baseline

Demographic and clinical characteristics Intervention group, N = 189 Control group, N = 188
Age (mean ± SD) 65.1 ± 11.4 66.3 ± 10.9
Female, n (%) 87 (46) 73 (39)
Male, n (%) 102 (54) 115 (61)
Body mass index (BMI) (mean ± SD) 30.1 ± 5 30.2 ± 5.2
BMI category, n (%)
 18.5–25 kg/m2 24 (12.7) 27 (14.4)
 25–30 kg/m2 78 (41.3) 76 (40.4)
 > 30 kg/m2 87 (46) 85 (45.2)
Diabetes anteriority (in years) (mean ± SD) 10.7 ± 8.2 10.2 ± 7.9
Smoking, n/N (%) 23/186 (12.4) 24/186 (12.9)
Alcohol consumption, n/N (%) 30/187 (16) 49/185 (25.9)
Pill organizer usage, n/N (%) 58/188 (30.9) 62/185 (33.5)
Oral antidiabetic treatment, n (%) N = 188 N = 186
 Monotherapy 57 (30.3) 64 (34.4)
 Bitherapy 74 (39.4) 79 (42.5)
 Tritherapy 57 (30.3) 43 (23.1)
Type of antidiabetic treatment alone or in combination, n (%)
 Biguanides 181 (95.8) 175 (93.1)
 Sulfonylurea 92 (48.7) 88 (46.8)
 DPP-4 inhibitors 95 (50.2) 86 (45.7)
 Glinides 24 (12.7) 22 (11.7)
 Alpha-glucosidase inhibitors 6 (3.2) 4 (2.1)
Antihypertension treatment, n/N (%) 124/157 (79.0) 126/158 (79.7)
Hypolipidemic treatment, n/N (%) 116/157 (73.9) 121/158 (76.6)
Biologic values (mean ± SD)
 HbA1c % 7.9 ± 1.0 7.7 ± 0.8
 Fasting plasma glucose (g/l) 1.6 ± 0.4 1.6 ± 0.5
 Total cholesterol (mg/dl) 1.9 ± 0.4 2.0 ± 0.7
 LDL-c (mg/dl) 110 ± 40 110 ± 50
Blood pressure (mean ± SD)
 Systolic blood pressure (mmHg) 134.8 ± 11.6 136.1 ± 11.3
 Diastolic blood pressure (mmHg) 78.1 ± 9.3 79.1 ± 9.2

No significant differences in demographic or clinical characteristics were observed between the two groups at baseline

When specified, N = number of patients for which data were available. Missing data were excluded from the analysis

When not specified, N = total number of patients included in each group